Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts
- PMID: 33716195
- PMCID: PMC8433257
- DOI: 10.1016/j.ijid.2021.02.107
Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts
Abstract
The October 2020 Global TB report reviews TB control strategies and United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York. Progress in TB care and prevention has been very slow. In 2019, TB remained the most common cause of death from a single infectious pathogen. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208, 000 deaths among people living with HIV. Adults accounted for 88% and children for 12% of people with TB. The WHO regions of South-East Asia (44%), Africa (25%), and the Western Pacific (18%) had the most people with TB. Eight countries accounted for two thirds of the global total: India (26%), Indonesia (8.5%), China (8.4%), the Philippines (6.0%), Pakistan (5.7%), Nigeria (4.4%), Bangladesh (3.6%) and South Africa (3.6%). Only 30% of the 3.5 million five-year target for children treated for TB was met. Major advances have been development of new all oral regimens for MDRTB and new regimens for preventive therapy. In 2020, the COVID-19 pandemic dislodged TB from the top infectious disease cause of mortality globally. Notably, global TB control efforts were not on track even before the advent of the COVID-19 pandemic. Many challenges remain to improve sub-optimal TB treatment and prevention services. Tuberculosis screening and diagnostic test services need to be ramped up. The major drivers of TB remain undernutrition, poverty, diabetes, tobacco smoking, and household air pollution and these need be addressed to achieve the WHO 2035 TB care and prevention targets. National programs need to include interventions for post-tuberculosis holistic wellbeing. From first detection of COVID-19 global coordination and political will with huge financial investments have led to the development of effective vaccines against SARS-CoV2 infection. The world now needs to similarly focus on development of new vaccines for TB utilizing new technological methods.
Keywords: Global TB Report 2020; Prevention; Treatment; Tuberculosis.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflicts of interest
All authors declare no conflicts of interest
All authors have a specialist interest in TB. All authors declare no conflicts of interest.
Similar articles
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
Situational analysis of 10 countries with a high burden of drug-resistant tuberculosis 2 years post-UNHLM declaration: progress and setbacks in a changing landscape.Int J Infect Dis. 2021 Jul;108:557-567. doi: 10.1016/j.ijid.2021.06.022. Epub 2021 Jun 15. Int J Infect Dis. 2021. PMID: 34139370
-
The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.Lancet Respir Med. 2018 Apr;6(4):299-314. doi: 10.1016/S2213-2600(18)30057-2. Lancet Respir Med. 2018. PMID: 29595511 Review.
-
Recovering from the Impact of the Covid-19 Pandemic and Accelerating to Achieving the United Nations General Assembly Tuberculosis Targets.Int J Infect Dis. 2021 Dec;113 Suppl 1:S100-S103. doi: 10.1016/j.ijid.2021.02.078. Epub 2021 Mar 11. Int J Infect Dis. 2021. PMID: 33716198 Free PMC article.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
Cited by
-
Genetic insights into the connection between pulmonary TB and non-communicable diseases: An integrated analysis of shared genes and potential treatment targets.PLoS One. 2024 Oct 21;19(10):e0312072. doi: 10.1371/journal.pone.0312072. eCollection 2024. PLoS One. 2024. PMID: 39432502 Free PMC article.
-
Design, synthesis and computational studies of new azaheterocyclic coumarin derivatives as anti-Mycobacterium tuberculosis agents targeting enoyl acyl carrier protein reductase (InhA).RSC Adv. 2024 Jul 9;14(30):21763-21777. doi: 10.1039/d4ra02746a. eCollection 2024 Jul 5. RSC Adv. 2024. PMID: 38984262 Free PMC article.
-
Host-directed therapy against mycobacterium tuberculosis infections with diabetes mellitus.Front Immunol. 2024 Jan 8;14:1305325. doi: 10.3389/fimmu.2023.1305325. eCollection 2023. Front Immunol. 2024. PMID: 38259491 Free PMC article. Review.
-
Tuberculosis-Associated Anemia: A Narrative Review.Cureus. 2022 Aug 7;14(8):e27746. doi: 10.7759/cureus.27746. eCollection 2022 Aug. Cureus. 2022. PMID: 36106202 Free PMC article. Review.
-
Knowledge and Attitudes of Indonesian General Practitioners Towards the Isoniazid Preventive Therapy Program in Indonesia.J Prev Med Public Health. 2022 Sep;55(5):428-435. doi: 10.3961/jpmph.22.248. Epub 2022 Aug 5. J Prev Med Public Health. 2022. PMID: 36229905 Free PMC article.
References
-
- African Union. Assembly of the African Union 8th Ordinary Session. . p. 164.
-
- Bisimwa BC, Nachega JB, Warren RM, Theron G, Metcalfe JZ, Shah M, et al. Xpert Mycobacterium tuberculosis/Rifampicin–Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications. Clin Infect Dis 2020;26:ciaa873, doi:10.1093/cid/ciaa873. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
